JP2024518539A5 - - Google Patents

Info

Publication number
JP2024518539A5
JP2024518539A5 JP2023570121A JP2023570121A JP2024518539A5 JP 2024518539 A5 JP2024518539 A5 JP 2024518539A5 JP 2023570121 A JP2023570121 A JP 2023570121A JP 2023570121 A JP2023570121 A JP 2023570121A JP 2024518539 A5 JP2024518539 A5 JP 2024518539A5
Authority
JP
Japan
Prior art keywords
seq
group
complex according
polypeptide complex
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023570121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518539A (ja
JP7888613B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027688 external-priority patent/WO2022240637A2/en
Publication of JP2024518539A publication Critical patent/JP2024518539A/ja
Publication of JP2024518539A5 publication Critical patent/JP2024518539A5/ja
Application granted granted Critical
Publication of JP7888613B2 publication Critical patent/JP7888613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023570121A 2021-05-12 2022-05-04 抗体を標的とする腫瘍によって活性化されるegfrおよびエフェクター細胞抗原に関する組成物および方法 Active JP7888613B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163187690P 2021-05-12 2021-05-12
US63/187,690 2021-05-12
US202263327317P 2022-04-04 2022-04-04
US63/327,317 2022-04-04
PCT/US2022/027688 WO2022240637A2 (en) 2021-05-12 2022-05-04 Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens

Publications (3)

Publication Number Publication Date
JP2024518539A JP2024518539A (ja) 2024-05-01
JP2024518539A5 true JP2024518539A5 (cg-RX-API-DMAC7.html) 2025-05-08
JP7888613B2 JP7888613B2 (ja) 2026-07-13

Family

ID=84029363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570121A Active JP7888613B2 (ja) 2021-05-12 2022-05-04 抗体を標的とする腫瘍によって活性化されるegfrおよびエフェクター細胞抗原に関する組成物および方法

Country Status (12)

Country Link
US (3) US12161724B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337697A4 (cg-RX-API-DMAC7.html)
JP (1) JP7888613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240035392A (cg-RX-API-DMAC7.html)
CN (1) CN117642156A (cg-RX-API-DMAC7.html)
AR (1) AR125758A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022272906A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023650A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218661A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013382A (cg-RX-API-DMAC7.html)
TW (1) TW202311289A (cg-RX-API-DMAC7.html)
WO (1) WO2022240637A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116981682A (zh) * 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
WO2025195305A1 (en) * 2024-03-16 2025-09-25 Vibrant Pharma Limited Multispecific antigen binding proteins and uses thereof
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201560A1 (en) * 2024-03-29 2025-10-02 Vibrant Pharma Limited Multispecific antigen-binding proteins and uses thereof
WO2026067689A1 (zh) * 2024-09-28 2026-04-02 浙江道尔生物科技有限公司 肿瘤特异性激活的蛋白药物及其应用
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
PE20150605A1 (es) * 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
JP6092649B2 (ja) 2013-02-15 2017-03-08 キヤノン株式会社 演算装置、アレイ型演算装置およびその制御方法、情報処理システム
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN105820248A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
US20230220105A1 (en) 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
US20230312729A1 (en) 2019-06-26 2023-10-05 Amunix Pharmaceuticals, Inc. Egfr antigen binding fragments and compositions comprising same
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
KR20210043475A (ko) 2019-10-10 2021-04-21 주식회사 와이바이오로직스 다중 특이적 융합 단백질 및 이의 용도
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
WO2022094299A2 (en) 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
CN116981682A (zh) 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
CN117616137A (zh) 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4615514A2 (en) 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2024100451A2 (en) 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens

Similar Documents

Publication Publication Date Title
JP2023552812A5 (cg-RX-API-DMAC7.html)
JP2020186248A5 (cg-RX-API-DMAC7.html)
CN113412281B (zh) Btn3a结合蛋白及其用途
JP7209464B2 (ja) ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体
JP2022535924A5 (cg-RX-API-DMAC7.html)
JP2021159081A5 (cg-RX-API-DMAC7.html)
JP2020505919A5 (cg-RX-API-DMAC7.html)
US10738103B2 (en) Antibody light chains
JP2021502984A (ja) Fx活性化を促進する第x因子結合剤
Tillib “Camel nanoantibody” is an efficient tool for research, diagnostics and therapy
JP2020531430A (ja) 抗体を標的とする抗ctla4プロボディ療法
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2024507540A5 (cg-RX-API-DMAC7.html)
JP2005528914A5 (cg-RX-API-DMAC7.html)
JP2023552462A5 (cg-RX-API-DMAC7.html)
JP2021506310A5 (cg-RX-API-DMAC7.html)
JP2022500455A5 (cg-RX-API-DMAC7.html)
US20240019424A1 (en) Method for resolving complex, multistep antibody interactions
TWI789399B (zh) 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
CN121866271A (zh) 靶向表皮生长因子受体的组合物及其制备和使用方法
CN113544157B (zh) 用于检测或捕获样品中的多肽的抗体和组合物,以及用于检测或捕获样品中的多肽的方法
JP2025513930A5 (cg-RX-API-DMAC7.html)
US20230227536A1 (en) Immunogenicity-reduced low-molecular antibody and method for producing same
WO2024061224A1 (zh) 抗her2抗体及其用途
KR20250012612A (ko) 고형 종양을 치료하는 방법